Worldwide Clinical Trials

Ovarian cancer remains one of the most complex areas in oncology research. Worldwide has extensive experience managing ovarian cancer trials, giving sponsors the tools to start fast and scale seamlessly. Over the last five years, we’ve: 💠 Managed FIH to 400+ patient Phase III trials 💠 Partnered with 300 sites across 13 countries 💠 Supported Fast Track and Accelerated Approval Pathways 💠 Collaborated with leading cooperative groups like GOG and ENGOT Our biopharma-focused, people-first approach drives the continuity, agility, and execution needed across every phase of development. Explore how we’re navigating these complexities in our recent fact sheet ���� https://ow.ly/og5G50YCQUY If you’ll be at the Society of Gynecologic Oncology Annual Meeting April 10-13, connect with our team to continue this conversation. #OncologyDrugDevelopment #Biopharma #GynecologicOncology #OncologyResearch

If you want your team to stay ahead in bioanalysis, this event is for you. 🗓️ Join our team at WRIB, April 13-17 in Dallas, TX, where 1,000+ professionals across pharma, biotech, CROs, and regulatory agencies come together to explore the latest in bioanalysis. Worldwide’s Jingguo Hou, Sam Hanley, Xiaodong Zhu, Steven Hoehne, Alicia Bian, and Jason Hamilton will present a poster, “Increased Sensitivity and Improved Assay Quality Using a Novel LC–MS/MS Strategy for GLP Analysis of Epinephrine in Human Plasma,” demonstrating new ways to improve sensitivity and assay performance in bioanalysis. Stop by booth #16 to connect with our team: https://ow.ly/apFL50YCmgC

Are you headed to Chief Medical Officer 360º? Join our Worldwide team April 13-14 in Boston as we connect with CMOs across indications, modalities, companies, and experience levels to exchange real-world insights and gain practical skills. Be sure to catch Michael Murphy M.D., Ph.D.’s presentation, “Reframing the IND: From Tactical Requirement to Strategic Opportunity,” where you’ll gain insights into turning early regulatory milestones into strategic advantages for clinical development. Schedule a meeting with our team: https://ow.ly/gcgB50YBJk8

Designing neurodegeneration trials requires the right operational strategy from the start. In this checklist, we break down key considerations for your trial design, such as: 💠 Site infrastructure and study partners 💠 Participant selection 💠 Clinical outcomes and assessment scales 💠 Patient lived experience Download it at https://ow.ly/lcjO50YAZt7

What if autoimmune diseases could be treated at their source, not just managed? In this video, Dr. Panteli Theocharous discusses how new approaches, from CAR-T therapies to circular RNA technologies, are creating more targeted, durable treatments by addressing the underlying immune dysfunction. Watch it below.

Huge congratulations to the team at ImmunoBrain. The results of their phase 1b study of IBC-Ab002, an inhibitory immune checkpoint blockade therapeutic approach (the IBC-01-01 study) were presented by Professor catherine mummery at ADPD in Copenhagen last week. It has been an honor for us to support this latest significant milestone within the dedicated scientific research and translational medicine by Professor Michal Schwartz which targets the peripheral immune system to benefit the brain - in this instance in Alzheimer's Disease. https://lnkd.in/dcSYhcXE #Immunobrain #worldwideclinicaltrials #ADPD2026

Great to see the positive momentum coming out of the Phase III X-TOLE2 study— especially fitting for us to share on #PurpleDay, a day to raise awareness about epilepsy and support those living with the condition. The topline results from Xenon Pharmaceuticals Inc.'s program in focal onset seizures are very encouraging! Congratulations to the Xenon team, and we appreciate the continued collaboration in advancing care for people living with epilepsy.

Why are ovarian cancer trials among the most complex in oncology? In this article, Susan Albert VP of Oncology Drug Development, explores these complexities; from biomarker-driven stratification, to evolving regulatory criteria and global coordination. The takeaway: thoughtful planning early on helps teams start fast and scale seamlessly, even in the most intricate oncology programs. Read it here: https://ow.ly/uI7i50YyHff If you’ll be at the Society of Gynecologic Oncology Annual Meeting April 10-13, connect with our team to continue this conversation. 💬 #ClinicalTrials #OncologyDrugDevelopment #GynecologicOncology #OncologyResearch

For many patients, the biggest barrier to a clinical trial isn’t eligibility, it’s location. Cross-border enrollment is becoming an important strategy to expand access to trials for patients who don’t have options in their home country. In this webinar featuring Worldwide’s Nathan Chadwick, we break down: 💠How cross-border enrollment works, and when to use it 💠Key regulatory and logistical challenges 💠Different enrollment models, including in-country stay versus travel 💠How Worldwide implements complex cross-border enrollment strategies Watch it here: https://ow.ly/sO2U50Yy5hz